Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M

Pharmaceutical Maker Razneron Announcement on Monday It will buy the genetic testing company for $ 23 and $ 256 million after the bankruptcy auction.

Razneron said that it would achieve the 23ndme genomics service as part of the contract and the personal and genetic data bank of 15 million customers. Pharma Giants say they plan to use 23andme customer data to help discover drugs and “It will prioritize 23ndme’s customer data privacy, protection and moral use.”

23 OME In March After a data violation of 7 million customers have exposed personal and genetic data 2023 across. The company’s interest in the company’s DNA test kit has also been submerged near the company’s share price. 23 OME’s founder and CEO, Ann Wajiki, has resigned after the fall of the company.

After filing, a federal bankruptcy court was appointed to oversee the sale of 23andme assets, expressed concern that customer data stores Can be sold to hostile countries or immoral buyersThe

In his statement, Razneron said that as a buyer named at the bankruptcy auction, it wants to “confirm” with 23andme’s privacy policy and the laws of customer information.

The bankruptcy court is ready to consider the acquisition of the June 1 June. Razneron said that it would not achieve the 21st lemonade health business.